Nasopharyngeal Cancinoma (NPC) Clinical Trials

20 recruiting

Nasopharyngeal Cancinoma (NPC) Trials at a Glance

20 actively recruiting trials for nasopharyngeal cancinoma (npc) are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 9 trials, with the heaviest enrollment activity in Guangzhou, Shanghai, and Changsha. Lead sponsors running nasopharyngeal cancinoma (npc) studies include Sun Yat-sen University, Sun Yat-Sen University Cancer Center, and Hai-Qiang Mai,MD,PhD.

Browse nasopharyngeal cancinoma (npc) trials by phase

Treatments under study

About Nasopharyngeal Cancinoma (NPC) Clinical Trials

Looking for clinical trials for Nasopharyngeal Cancinoma (NPC)? There are currently 20 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Nasopharyngeal Cancinoma (NPC) trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Nasopharyngeal Cancinoma (NPC) clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 20 trials

Recruiting
Phase 2

LDRT Combined With Toripalimab and Chemotherapy for Recurrent/Metastatic NPC

Nasopharangeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-sen University55 enrolled1 locationNCT07325539
Recruiting
Phase 1Phase 2

A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers

Squamous Cell CarcinomaAdvanced or Metastatic Squamous Non-Small Cell Lung CancerAdvanced Head and Neck Squamous Cell Carcinoma+4 more
Hummingbird Bioscience398 enrolled20 locationsNCT05910827
Recruiting
Phase 2

Becotatug Vedotin for LA-NPC With a Suboptimal Response to Induction Chemotherapy Combined With Immunotherapy

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University59 enrolled1 locationNCT07496190
Recruiting
Phase 3

Reduced-dose vs Standard-dose Irradiation for Low-risk Clinical Target Volume in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University700 enrolled6 locationsNCT07201337
Recruiting
Phase 2

LDRT and Chemoimmunotherapy in NPC With Liver Metastasis

Nasopharyngeal Cancinoma (NPC)
Hunan Cancer Hospital26 enrolled7 locationsNCT06788002
Recruiting
Phase 2

Toripalimab Combined With Different Platinum-Based Induction Chemotherapy Regimens for Locally Advanced Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University243 enrolled4 locationsNCT07362979
Recruiting

IMRT Alone for Stage IB Nasopharyngeal Carcinoma Without High-Risk Features

Nasopharyngeal Cancinoma (NPC)
Qiaojuan Guo169 enrolled1 locationNCT07376603
Recruiting
Phase 3

Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid

Nasopharyngeal Cancinoma (NPC)Radiation-induced Oral Mucositis
Sun Yat-sen University244 enrolled16 locationsNCT07311772
Recruiting
Phase 3

Phase 3 Trial Comparing IMRT or IMPT Plus CIRT for Patients With NPC

Nasopharyngeal Cancinoma (NPC)
Lin Kong, MD470 enrolled1 locationNCT06846450
Recruiting
Phase 3

Adaptive Immunotherapy for Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University802 enrolled1 locationNCT07154069
Recruiting

Prospective Immuno-Radiomic Profiling in Nasopharyngeal Carcinoma Treated With Proton or Photon Chemoradiotherapy

Nasopharyngeal Cancinoma (NPC)NPC Patients
Cheng-En Hsieh500 enrolled1 locationNCT07232680
Recruiting
Phase 2

Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy

Nasopharyngeal Cancinoma (NPC)
Fudan University76 enrolled1 locationNCT07067268
Recruiting
Phase 2

SBRT Combined With Nimotuzumab and Tislelizumab for Oligoprogressive Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of Immunotherapy

ImmunotherapySBRTNasopharyngeal Cancinoma (NPC)
The First Affiliated Hospital of Xiamen University20 enrolled2 locationsNCT06676722
Recruiting
Phase 3

QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.

Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 1Phase 2

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)Metastatic Nasopharyngeal CarcinomaRecurrent Nasopharynx Carcinoma
Sun Yat-Sen University Cancer Center148 enrolled1 locationNCT06802835
Recruiting
Phase 3

Reduced Dose Radiotherapy vs Standard Dose Radiotherapy for Early Stage Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Hai-Qiang Mai,MD,PhD342 enrolled1 locationNCT06912698
Recruiting
Phase 2Phase 3

Sodium Bicarbonate for Reducing Radiation-Induced Oral Mucositis in Nasopharyngeal Carcinoma.

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University196 enrolled1 locationNCT06854510
Recruiting

Development and Validation of a Deep Learning Model to Predict Distant Metastases in Nasopharyngeal Carcinoma Using Whole Slide Imaging and MRI

Nasopharyngeal Cancinoma (NPC)Distant Metastasis
Sun Yat-sen University500 enrolled2 locationsNCT06831357
Recruiting

A Deep Learning Model for Diagnosing Lymph Node Metastasis in Nasopharyngeal Carcinoma(NPC)

Lymph Node MetastasisNasopharyngeal Cancinoma (NPC)
Sun Yat-sen University500 enrolled1 locationNCT06829147
Recruiting
Phase 3

Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma

Nasopharyngeal Cancinoma (NPC)
Sun Yat-sen University242 enrolled1 locationNCT06669611